跳至主要内容
临床试验/ACTRN12612000959875
ACTRN12612000959875已完成2 期

Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.

Protemix Corporation, Ltd.0 个研究点目标入组 120 人开始时间: 2012年9月6日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
30 Years 至 70 Years(—)
性别
All

入选标准

  • Men and women between 30 to 70 years of age with poor blood glucose control, retinopathy and nephropathy resulting from Type 2 diabetes mellitus.

排除标准

  • Healthy volunteers excluded, and those with with poor blood glucose control, retinopathy and nephropathy resulting from Type 2 diabetes mellitus, but outside of the age range above

研究者

发起方
Protemix Corporation, Ltd.

相似试验